Posted by Michael Wonder on 20 Aug 2022
European Commission approves Celltrion Healthcare’s Vegzelma (CT-P16, biosimilar bevacizumab) for the treatment of multiple types of cancer
18 August 2022 - Vegzelma offers European patients living with certain types of breast, lung, renal, colon, rectum, ovarian and cervical cancers a new, safe, and effective treatment option at an affordable price.
Celltrion Healthcare announced today that the European Commission has approved Vegzelma (CT-P16), a biosimilar bevacizumab referencing EU approved Avastin, for the treatment of metastatic breast cancer, non-small-cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
